What are the current clinical development trends, and how do we at KCR respond to them?

KCR Chief Medical Officer, dr. Anna Baran, is sharing her thoughts on that.
What we currently see in our portfolio is increasing proportion of drugs which are aimed for easier administration.
Which means that we see oral drugs as opposed to predominance of intra-tumoral, intralesional or intracranial drugs, we have been researching and developing for the last couple of years.
What does it mean?
In my opinion, it's super important for the global healthcare because it will allow to better manage their resources. And they are clearly under a resourcing burden still post-pandemic.
In addition, what we have to stay focused or where we will have to stay focused, is our attention to rare patient populations or rare subpopulations of given cancers because these may actually benefit from higher degree of intervention.
Which means increased cost, increased effort and healthcare resources.
But eventually these patients will definitely benefit because we have to work towards extending their lives and their quality of lives.